Table 3.
The Safety and Efficacy of COVID-19 Vaccines of the Included Studies
| S. No. | Authors (Year) | COVID-19 Vaccine Used in the Study | Outcome |
|---|---|---|---|
| 1 | Bravo et al28 (2022) | SCB-2019 vaccine | Safe and effective |
| 2 | Thomas et al15 (2021) | BNT162b2 Vaccine through 6 months | Safe and effective |
| 3 | Moreira et al16 (2022) | Third dose of BNT162b2 vaccine | Safe and effective |
| 4 | Sadoff et al17 (2022) | Single-dose Ad26.COV2.S vaccine | Safe and effective but not effective against delta variant was (VE=−5.7%) |
| 5 | Takuva et al13 (2022) | Single-dose Ad26.COV2.S vaccine | Safe and effective |
| 6 | Hardt et al19 (2022) | A booster regimen of Ad26.COV2.S | Safe and effective |
| 7 | Madhi et al20 (2022) | NVX-CoV2373 vaccine | Favorable safety and immunogenicity |
| 8 | Madhi et al21 (2021) | ChAdOx1nCoV-19 (AZD1222) in people living with and without HIV | Favorable safety and immunogenicity |
| 9 | Zhang et al11 (2022) | BBIBP‑CorV (Sinopharm) | Safe and effective |
| 10 | Hammad et al12 (2022) | Oxford/AstraZeneca (ChAdOx1/nCoV-19) during Delta and Omicron Variants Pandemic | Safe and effective |
| 11 | Madhi et al22 (2021) | ChAdOx1nCoV-19 (AZD1222) vaccine against the B.1.351 Variant | Not-effective against B.1.351 variant (VE=10.4%) |
| 12 | Shinde et al29 (2021) | NVX-CoV2373 vaccine against the B.1.351 Variant | Safe and effective |
| 13 | Gray et al14 (2022) | Ad26.COV2.S and BNT162b2 vaccines against Omicron Variant | Both vaccines were equally effective |